Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of AZD4831 Formulations in Healthy Volunteers
NCT05457270Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mitiperstat in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by AstraZeneca. Primary endpoints: Relative bioavailability at Day 14, Maximum observed plasma drug concentration at Day 14 and 7 more. Started Aug 2022; status: completed.
02
Drugs
mitiperstat
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05457270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05457270.